Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Fiona M Ross, Hervé Avet-Loiseau, Geneviève Ameye, Norma C Gutiérrez, Peter Liebisch, Sheila O'Connor, Klara Dalva, Sonia Fabris, Adele M Testi, Marie Jarosova, Clare Hodkinson, Anna Collin, Gitte Kerndrup, Petr Kuglik, Dariusz Ladon, Paolo Bernasconi, Brigitte Maes, Zuzana Zemanova, Kyra Michalova, Lucienne Michau & 11 others Kai Neben, N Emil U Hermansen, Katrina Rack, Alberto Rocci, Rebecca Protheroe, Laura Chiecchio, Hélène A Poirel, Pieter Sonneveld, Mette Nyegaard, Hans Erik Johnsen, on behalf of the European Myeloma Network

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or break-apart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.
Original languageEnglish
JournalHaematologica
Volume97
Issue number8
Pages (from-to)1272-1277
ISSN0390-6078
DOIs
Publication statusPublished - 2012

Fingerprint

Interphase
Databases
Education
Plasma Cells
Consensus

Cite this

Ross, F. M., Avet-Loiseau, H., Ameye, G., Gutiérrez, N. C., Liebisch, P., O'Connor, S., ... on behalf of the European Myeloma Network (2012). Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica, 97(8), 1272-1277. https://doi.org/10.3324/haematol.2011.056176
Ross, Fiona M ; Avet-Loiseau, Hervé ; Ameye, Geneviève ; Gutiérrez, Norma C ; Liebisch, Peter ; O'Connor, Sheila ; Dalva, Klara ; Fabris, Sonia ; Testi, Adele M ; Jarosova, Marie ; Hodkinson, Clare ; Collin, Anna ; Kerndrup, Gitte ; Kuglik, Petr ; Ladon, Dariusz ; Bernasconi, Paolo ; Maes, Brigitte ; Zemanova, Zuzana ; Michalova, Kyra ; Michau, Lucienne ; Neben, Kai ; Hermansen, N Emil U ; Rack, Katrina ; Rocci, Alberto ; Protheroe, Rebecca ; Chiecchio, Laura ; Poirel, Hélène A ; Sonneveld, Pieter ; Nyegaard, Mette ; Johnsen, Hans Erik ; on behalf of the European Myeloma Network. / Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. In: Haematologica. 2012 ; Vol. 97, No. 8. pp. 1272-1277.
@article{9977947d499045ce9d1de05feb788b78,
title = "Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders",
abstract = "The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10{\%} for fusion or break-apart probes, 20{\%} for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.",
author = "Ross, {Fiona M} and Herv{\'e} Avet-Loiseau and Genevi{\`e}ve Ameye and Guti{\'e}rrez, {Norma C} and Peter Liebisch and Sheila O'Connor and Klara Dalva and Sonia Fabris and Testi, {Adele M} and Marie Jarosova and Clare Hodkinson and Anna Collin and Gitte Kerndrup and Petr Kuglik and Dariusz Ladon and Paolo Bernasconi and Brigitte Maes and Zuzana Zemanova and Kyra Michalova and Lucienne Michau and Kai Neben and Hermansen, {N Emil U} and Katrina Rack and Alberto Rocci and Rebecca Protheroe and Laura Chiecchio and Poirel, {H{\'e}l{\`e}ne A} and Pieter Sonneveld and Mette Nyegaard and Johnsen, {Hans Erik} and {on behalf of the European Myeloma Network}",
year = "2012",
doi = "10.3324/haematol.2011.056176",
language = "English",
volume = "97",
pages = "1272--1277",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

Ross, FM, Avet-Loiseau, H, Ameye, G, Gutiérrez, NC, Liebisch, P, O'Connor, S, Dalva, K, Fabris, S, Testi, AM, Jarosova, M, Hodkinson, C, Collin, A, Kerndrup, G, Kuglik, P, Ladon, D, Bernasconi, P, Maes, B, Zemanova, Z, Michalova, K, Michau, L, Neben, K, Hermansen, NEU, Rack, K, Rocci, A, Protheroe, R, Chiecchio, L, Poirel, HA, Sonneveld, P, Nyegaard, M, Johnsen, HE & on behalf of the European Myeloma Network 2012, 'Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders', Haematologica, vol. 97, no. 8, pp. 1272-1277. https://doi.org/10.3324/haematol.2011.056176

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. / Ross, Fiona M; Avet-Loiseau, Hervé; Ameye, Geneviève; Gutiérrez, Norma C; Liebisch, Peter; O'Connor, Sheila; Dalva, Klara; Fabris, Sonia; Testi, Adele M; Jarosova, Marie; Hodkinson, Clare; Collin, Anna; Kerndrup, Gitte; Kuglik, Petr; Ladon, Dariusz; Bernasconi, Paolo; Maes, Brigitte; Zemanova, Zuzana; Michalova, Kyra; Michau, Lucienne; Neben, Kai; Hermansen, N Emil U; Rack, Katrina; Rocci, Alberto; Protheroe, Rebecca; Chiecchio, Laura; Poirel, Hélène A; Sonneveld, Pieter; Nyegaard, Mette; Johnsen, Hans Erik; on behalf of the European Myeloma Network.

In: Haematologica, Vol. 97, No. 8, 2012, p. 1272-1277.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

AU - Ross, Fiona M

AU - Avet-Loiseau, Hervé

AU - Ameye, Geneviève

AU - Gutiérrez, Norma C

AU - Liebisch, Peter

AU - O'Connor, Sheila

AU - Dalva, Klara

AU - Fabris, Sonia

AU - Testi, Adele M

AU - Jarosova, Marie

AU - Hodkinson, Clare

AU - Collin, Anna

AU - Kerndrup, Gitte

AU - Kuglik, Petr

AU - Ladon, Dariusz

AU - Bernasconi, Paolo

AU - Maes, Brigitte

AU - Zemanova, Zuzana

AU - Michalova, Kyra

AU - Michau, Lucienne

AU - Neben, Kai

AU - Hermansen, N Emil U

AU - Rack, Katrina

AU - Rocci, Alberto

AU - Protheroe, Rebecca

AU - Chiecchio, Laura

AU - Poirel, Hélène A

AU - Sonneveld, Pieter

AU - Nyegaard, Mette

AU - Johnsen, Hans Erik

AU - on behalf of the European Myeloma Network

PY - 2012

Y1 - 2012

N2 - The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or break-apart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.

AB - The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analyzed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise, there was acceptable agreement on more than 1,000 tests. The conclusions from the exercise were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) material should be part of the first draw of the aspirate; 2) samples should be sent at suitable times to allow for the lengthy processing procedure; 3) most importantly, PCs must be purified or specifically identified; 4) positive cut-off levels should be relatively conservative: 10% for fusion or break-apart probes, 20% for numerical abnormalities; 5) informative probes should be combined to best effect; 6) in specialist laboratories, a single experienced analyst is considered adequate; 7) at least 100 PC should be scored; 8) essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) suitable commercial probes should be available for clinically relevant abnormalities; 10) the clinical report should be expressed clearly and must state the percentage of PC involved and the method used for identification; 11) a retrospective European based FISH data bank linked to clinical data should be generated; and 12) prospective analysis should be centralized for upcoming trials based on the recommendations made. The European Myeloma Network aims to build on these recommendations to establish standards for a common European data base to define subgroups with prognostic significance.

U2 - 10.3324/haematol.2011.056176

DO - 10.3324/haematol.2011.056176

M3 - Journal article

VL - 97

SP - 1272

EP - 1277

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -